Inventor · disambiguated record
Ahmed Hamdy
Also filed as: HAMDY AHMED
10 granted patents·14 pending applications·51 citations·filing 2013–2023
88Inventor score
Files withACERTA PHARMA BV24
Top patents by PatentIndex Score
24 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0591US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0688US9522917B2Bruton's tyrosine kinase inhibitors for hematopoietic mobilizationACERTA PHARMA BV·Filed 2013·Granted Dec 20, 2016·6 cites·22 claims
- 0786US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0884US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 0984US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1080US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1173US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1266US2019231775A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1364US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1463US2018193337A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 1562US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 1660US9937171B2Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2015·Granted Apr 10, 2018·0 cites·17 claims
- 1759US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 1858US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 1956US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 2056US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2154US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 2252US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2351US2017224819A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 2442US2017239351A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →